← Leaderboards
Mark Eamon Hayes
Zoneone Pharma, Inc.
$1,651,857
Attributed
$1,651,857
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $956.7K · FY2013–16$1M$750K$500K$250K$0
'13
'14
'15
'16
Funding mix
By agency
NIH$1,651,857 · 2
By mechanism
R44$1,491,193 · 1
R43$160,664 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAdultBloodBlood TransfusionBaseBone MarrowCause Of DeathCell TypeCessation Of LifeChelating AgentsBody WeightChildChildhoodClinical PathologyClinical Trials DesignCompliance BehaviorCyclic GmpDeferoxamineDesignDna Sequence AlterationDocumentationDoseChelation TherapyDrug Kinetics
Grant awards (3)
Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$956,715
R44 · FY2016 · HD · contact PI
Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$534,478
R44 · FY2015 · HD · contact PI
Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$160,664
R43 · FY2013 · HD · contact PI